Abstract: Objective The aim of this study was to investigate the efficacy and safety of direct acting antiviral agents (DAAs) in the treatment of patients with chronic hepatitis C viral infection-induced liver cirrhosis (CHC-C). Methods 30 patients with CHC-C received DAAs treatment in our hospital between March 2016 and October 2017, and the genotype of hepatitis C virus was 1b type in all patients. The patients with CHC-C were divided into three groups, receiving sophibavi and ribavirin in group A, receiving sophibavi, repaavi plus ribavirin in group B, and took suopavir, daclatasvir and ribavirin in group C, with 10 cases in each group, and all patients were treated for 12 weeks. Serum HCV RNA loads were measured by reverse transcription polymerase chain reaction (RT-PCR), serum level of alanine aminotransferase (ALT), glutaminase (AST), total bilirubin (TBIL), blood urea nitrogen (BUN), serum creatinine (Cr), creatine kinase (CK) and creatine kinase isoenzyme (CK-MB) were measured. The extremely rapid virologic response(RVR), early virologic response(EVR) , end of treatment virologic response(ETVR) and sustained virologic response were compared among the groups. Results The RVR and ETVR in group B and in group C were 100%, all significantly higher than 40% and 50% in group A(P<0.05); at the end of 12 week DAAs treatment, serum ALT levels in group A, group B and group C were (24.2±6.7)IU/L, (22.3±5.6)IU/L and (25.3±4.6)IU/L, serum AST levels were (23.2±8.1)IU/L, (24.6±3.8)IU/L and (28.4±4.8)IU/L, not significantly different among them(P>0.05); serum albumin and renal function index in the three groups were not significantly different (P>0.05), serum creatine kinase levels in the three groups were (63.3±11.8)U/L, (68.5±8.9)U/L and (62.1±10.2) U/L, not significantly different (P>0.05); there were 7 patients reporting nausea, and fatigue in one, headache in one and palpitation in one in group A, nausea in four, fatigue in three, headache in one, palpitation in one and rash in one in group B, and nausea in five, fatigue in two, headache in one, palpitation in one and rash in one in group C. Conclusion DAAs is efficacious and safe in the treatment of patients with CHC-C with HCV genotype 1b infection.

Key words: Liver cirrhosis, Chronic hepatitis C, Direct antiviral drugs, Efficacy, Safety